近日,国家医保局公布通过2025年国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品目录调整形式审查的申报药品名单。在这场“大考”中,礼来与诺和诺德这两大降糖减重领域的巨头,均有重磅产品亮相。在市场看来,这款2025年在中国拿下糖尿病和减重两大适应症的药物,欲以“成人2型糖尿病”之名叩击医保大门。这是降糖减重赛道玩家心照不宣的策略,如此次公布的通过审查名单中,礼来的替尔泊肽与...
Source Link近日,国家医保局公布通过2025年国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品目录调整形式审查的申报药品名单。在这场“大考”中,礼来与诺和诺德这两大降糖减重领域的巨头,均有重磅产品亮相。在市场看来,这款2025年在中国拿下糖尿病和减重两大适应症的药物,欲以“成人2型糖尿病”之名叩击医保大门。这是降糖减重赛道玩家心照不宣的策略,如此次公布的通过审查名单中,礼来的替尔泊肽与...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.